2026-07-13 20:07:02
Click:
The Chinese in vitro diagnostic instrument industry has achieved a leapfrog development from 'import dependence' to 'domestic leading' in the past decade. The market size has surged from approximately 43 billion yuan in 2016 to over 118.5 billion yuan in 2023, with an average annual compound growth rate of 15.58%, firmly ranking as the second largest market in the world. The overall substitution rate of domestic products has exceeded 50%, accounting for over 70% in fields such as biochemistry and immunodiagnosis. Companies such as Mindray, New Industries, Antu, and Wanfu have taken the lead in breaking through core technologies such as fully automated chemiluminescence assembly lines, digital PCR, and microfluidic POCT, achieving a closed-loop system of 'equipment+reagents'. On the policy side, the 14th Five Year Plan for medical equipment planning, registration system, and normalized centralized procurement will work together to accelerate the entry of high-end products and market restructuring, and promote the evolution of testing equipment towards intelligence, miniaturization, and integration. The prototype of a smart laboratory is emerging, and AI driven sample pre-processing, automatic quality control, and result interpretation systems are gradually being implemented, increasing detection efficiency by more than 40%. Although core components such as high-precision optical systems and microfluidic chips still rely on imports, domestic research and development have been fully launched. The industry is shifting from 'scale expansion' to 'deep technological cultivation', becoming a key breakthrough for independent and controllable medical equipment.